{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T05:17:04Z","timestamp":1730956624460,"version":"3.28.0"},"reference-count":42,"publisher":"Rambam Health Corporation","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rambam Maimonides Med J"],"abstract":"<jats:p>This review examines the risk of developing celiac disease (CD) and other autoimmune diseases in individ\u00acuals receiving the rotavirus (RV) vaccine compared to the normal population. Celiac disease is a malabsorp\u00active, chronic, immune-mediated enteropathy involving the small intestine. The pathogenesis of CD is multifactorial, and mucosal immunity plays an important role in its development. Low mucosal IgA levels significantly increase the risk of developing the disease. Rotavirus is an infectious agent that causes diar\u00acrhea, particularly in children aged 0\u201324 months, and is frequently involved in diarrhea-related deaths in these children. An oral vaccine against RV has been developed. While it is effective on RV infection, it also contributes to increasing mucosal immunity. Studies have indicated that individuals immunized with the RV vaccine are at lower risk of developing CD than unvaccinated individuals. In addition, the mean age for developing CD autoimmunity may be higher in the vaccinated group than in controls receiving placebo. Additional studies that include children immunized with different RV vaccines and unvaccinated children would provide more meaningful results. Although current data suggest a possible association of RV vaccina\u00action with a reduced risk of developing CD and other autoimmune diseases, this remains an unanswered question that merits greater international investigation.<\/jats:p>","DOI":"10.5041\/rmmj.10450","type":"journal-article","created":{"date-parts":[[2021,8,25]],"date-time":"2021-08-25T11:37:21Z","timestamp":1629891441000},"page":"e0031","source":"Crossref","is-referenced-by-count":2,"title":["Is the Rotavirus Vaccine Really Associated with a Decreased Risk of Developing Celiac and Other Autoimmune Diseases?"],"prefix":"10.5041","volume":"12","author":[{"name":"Gulhane Faculty of Medicine, University of Health Sciences, Ankara, Turkey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibrahim","family":"Kiliccalan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2983","published-online":{"date-parts":[[2021,10,25]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1016\/S0140-6736(09)60254-3","article-title":"Coeliac disease","volume":"373","author":"Sabatino A","year":"2009","unstructured":"1. Di Sabatino A, Corazza GR. Coeliac disease. Lancet 2009;373:1480-93.","journal-title":"Lancet"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1080\/20469047.2018.1504431","article-title":"Coeliac disease","volume":"39","author":"JRG","year":"2019","unstructured":"2. Brown JRG, Singh P. Coeliac disease. Paediatr Int Child Health 2019;39:23-31.","journal-title":"Paediatr Int Child Health"},{"key":"ref2","unstructured":"3. \u015eiklar Z, \u00dcnalacak M, Dallar Y, Tanyer G. S\u0131f\u0131r-2 yas aras\u0131 ishalli \u00e7ocuklarda rotavir\u00fcs s\u0131kl\u0131\u011f\u0131 ve risk fakt\u00f6rleri [The frequency and risk factors of rotavirus in children aged zero-2 years with diarrhea]. Turkiye Klinikleri J Pediatr 2000;9:219-24. [Turkish]"},{"key":"ref3","unstructured":"4. Centers for Disease Control and Prevention. Rotavirus vaccination. Website for the CDC. Available at: https:\/\/www.cdc.gov\/vaccines\/vpd\/rotavirus\/index.html (accessed February 3, 2021)."},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5. Ogra PL, Faden H, Welliver RC. Vaccination strategies for mucosal immune responses. Clin Microbiol Rev 2001;14;430-45.","DOI":"10.1128\/CMR.14.2.430-445.2001"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.virusres.2014.06.016","article-title":"Rotaviruses","volume":"190","author":"Desselberger","year":"2014","unstructured":"6. Desselberger U. Rotaviruses. Virus Res 2014;190:75-96.","journal-title":"Virus Res"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s40272-018-0283-3","article-title":"Rotavirus vaccines: effectiveness, safety, and future directions","volume":"20","author":"Burnett","year":"2018","unstructured":"7. Burnett E, Parashar U, Tage J. Rotavirus vaccines: effectiveness, safety, and future directions. Paediatr Drugs 2018;20:223-33.","journal-title":"Paediatr Drugs"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/S1473-3099(14)70832-1","article-title":"Distribution of rotavirus strains and strain-specific effectiveness of the rotavirus vaccine after its introduction: a systematic review and meta-analysis","volume":"14","author":"Leshem","year":"2014","unstructured":"8. Leshem E, Lopman B, Glass R, et al. Distribution of rotavirus strains and strain-specific effectiveness of the rotavirus vaccine after its introduction: a systematic review and meta-analysis. Lancet Infect Dis 2014;14:847-56.","journal-title":"Lancet Infect Dis"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.15585\/mmwr.mm6541a3","article-title":"Status of new vaccine introduction - worldwide, September 2016","volume":"65","author":"Loharikar","year":"2016","unstructured":"9. Loharikar A, Dumolard L, Chu S, Hyde T, Goodman T, Mantel C. Status of new vaccine introduction - worldwide, September 2016. MMWR Morb Mortal Wkly Rep 2016;65:1136-40.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1016\/S0140-6736(13)62630-6","article-title":"Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian infants: a randomised, double-blind, placebo-controlled trial","volume":"383","author":"Bhandari","year":"2014","unstructured":"10. Bhandari N, Rongsen-Chandola T, Bavdekar A, et al. Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian infants: a randomised, double-blind, placebo-controlled trial. Lancet 2014;383: 2136-43.","journal-title":"Lancet"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"7328","DOI":"10.1016\/j.vaccine.2017.03.076","article-title":"The rotavirus vaccine development pipeline","volume":"37","author":"Kirkwood","year":"2019","unstructured":"11. Kirkwood CD, Ma LF, Carey ME, Steele AD. The rotavirus vaccine development pipeline. Vaccine 2019;37:7328-35.","journal-title":"Vaccine"},{"key":"ref11","unstructured":"12. World Health Organization. Prequalified vaccines [search page]. Available at: https:\/\/extranet.who.int\/pqweb\/vaccines\/prequalified-vaccines (accessed June 13, 2021)."},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"13. Wang FT, Mast TC, Glass RJ, Loughlin J, Seeger JD. Effectiveness of the pentavalent rotavirus vaccine in preventing gastroenteritis in the United States. Pediatrics 2010;125:e208-13.","DOI":"10.1542\/peds.2009-1246"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"14. Cortese MM, Immergluck LC, Held M, et al. Effectiveness of monovalent and pentavalent rotavirus vaccine. Pediatrics 2013;132:e25-33.","DOI":"10.1542\/peds.2012-3804"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1093\/infdis\/jir390","article-title":"Monovalent rotavirus vaccine provides protection against an emerging fully heterotypic G9P[4] rotavirus strain in Mexico","volume":"204","author":"Yen","year":"2011","unstructured":"15. Yen C, Figueroa JR, Uribe ES, et al. Monovalent rotavirus vaccine provides protection against an emerging fully heterotypic G9P[4] rotavirus strain in Mexico. J Infect Dis 2011;204:783-6.","journal-title":"J Infect Dis"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa052664","article-title":"Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine","volume":"354","author":"Vesikari","year":"2006","unstructured":"16. Vesikari T, Matson DO, Dennehy P, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006;354: 23-33.","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1097\/INF.0000000000000086","article-title":"Impact and effectiveness of RotaTeq\u00ae vaccine based on 3 years of surveillance following introduction of a rotavirus immunization program in Finland","volume":"32","author":"Vesikari","year":"2013","unstructured":"17. Vesikari T, Uhari M, Renko M, et al. Impact and effectiveness of RotaTeq\u00ae vaccine based on 3 years of surveillance following introduction of a rotavirus immunization program in Finland. Pediatr Infect Dis J 2013;32:1365-73.","journal-title":"Pediatr Infect Dis J"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa052434","article-title":"Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis","volume":"354","author":"Ruiz-Palacios","year":"2006","unstructured":"18. Ruiz-Palacios GM, P\u00e9rez-Schael I, Vel\u00e1zquez FR, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006;354:11-22.","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/S0140-6736(10)60755-6","article-title":"Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial","volume":"376","author":"Zaman","year":"2010","unstructured":"19. Zaman K, Dang DA, Victor JC, et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet 2010;376:615-23.","journal-title":"Lancet"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1056\/NEJMoa0904797","article-title":"Effect of human rotavirus vaccine on severe diarrhea in African infants","volume":"362","author":"Madhi","year":"2010","unstructured":"20. Madhi SA, Cunliffe NA, Steele D, et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med 2010;362:289-98.","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/S0140-6736(10)60889-6","article-title":"Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial","volume":"376","author":"Armah","year":"2010","unstructured":"21. Armah GE, Sow SO, Breiman RF, et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet 2010;376:606-14.","journal-title":"Lancet"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1056\/NEJMoa1609462","article-title":"Efficacy of a low-cost, heat-stable oral rotavirus vaccine in Niger","volume":"376","author":"Isanaka","year":"2017","unstructured":"22. Isanaka S, Guindo O, Langendorf C, et al. Efficacy of a low-cost, heat-stable oral rotavirus vaccine in Niger. N Engl J Med 2017;376:1121-30.","journal-title":"N Engl J Med"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"6228","DOI":"10.1016\/j.vaccine.2017.09.014","article-title":"A randomized phase III clinical trial to assess the efficacy of a bovine-human reassortant pentavalent rotavirus vaccine in Indian infants","volume":"35","author":"Kulkarni","year":"2017","unstructured":"23. Kulkarni PS, Desai S, Tewari T, et al. A randomized phase III clinical trial to assess the efficacy of a bovine-human reassortant pentavalent rotavirus vaccine in Indian infants. Vaccine 2017;35:6228-37.","journal-title":"Vaccine"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"24. Zanoni G, Navone R, Lunardi C, et al. In celiac disease, a subset of autoantibodies against transglutaminase binds toll-like receptor 4 and induces activation of monocytes. PLoS Med 2006;3:e358.","DOI":"10.1371\/journal.pmed.0030358"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1111\/j.1572-0241.2006.00741.x","article-title":"Rotavirus infection frequency and risk of celiac disease autoimmunity in early childhood: a longitudinal study","volume":"101","author":"Stene","year":"2006","unstructured":"25. Stene LC, Honeyman MC, Hoffenberg EJ. Rotavirus infection frequency and risk of celiac disease autoimmunity in early childhood: a longitudinal study. Am J Gastroenterol 2006;101:2333-40.","journal-title":"Am J Gastroenterol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1126\/science.aah5298","article-title":"Reovirus infection triggers inflammatory responses to dietary antigens and development of celiac disease","volume":"356","author":"Bouziat","year":"2017","unstructured":"26. Bouziat R, Hinterleitner R, Brown JJ, et al. Reovirus infection triggers inflammatory responses to dietary antigens and development of celiac disease. Science 2017;356:44-50.","journal-title":"Science"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"27. Kemppainen KM, Lyncy KF, Liu E, et al. Factors that increase risk of celiac disease autoimmunity after a gastrointestinal infection in early life. Clin Gastroenterol Hepatol 2017;15:694-702.e5.","DOI":"10.1016\/j.cgh.2016.10.033"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1097\/INF.0000000000001600","article-title":"Rotavirus vaccination and the risk of celiac disease or type 1 diabetes in Finnish children at early life","volume":"36","author":"Vaarala","year":"2017","unstructured":"28. Vaarala O, Jokinen J, Lahdenkari M, Leino T. Rotavirus vaccination and the risk of celiac disease or type 1 diabetes in Finnish children at early life. Pediatr Infect Dis J 2017;36:674-5.","journal-title":"Pediatr Infect Dis J"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s12916-021-02017-1","article-title":"Paediatric rotavirus vaccination, coeliac disease and type 1 diabetes in children: a population-based cohort study","volume":"19","author":"Inns","year":"2021","unstructured":"29. Inns T, Fleming K, Iturriza-G\u00f3mara M, Hungerford D. Paediatric rotavirus vaccination, coeliac disease and type 1 diabetes in children: a population-based cohort study. BMC Med 2021;19:147.","journal-title":"BMC Med"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1097\/INF.0000000000002281","article-title":"Rotavirus vaccination does not increase type 1 diabetes and may decrease celiac disease in children and adolescents","volume":"38","author":"Hemming-Harlo","year":"2019","unstructured":"30. Hemming-Harlo M, L\u00e4hdeaho M-L, M\u00e4ki M, Vesikari T. Rotavirus vaccination does not increase type 1 diabetes and may decrease celiac disease in children and adolescents. Pediatr Infect Dis J 2019;38:539-41.","journal-title":"Pediatr Infect Dis J"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1016\/S0140-6736(18)31320-5","article-title":"Type 1 diabetes","volume":"391","author":"DiMeglio","year":"2018","unstructured":"31. DiMeglio LA, Evans-Molina C, Oram RA. Type 1 diabetes. Lancet 2018;391:2449-62.","journal-title":"Lancet"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S0140-6736(13)60591-7","article-title":"Type 1 diabetes","volume":"383","author":"Atkinson","year":"2014","unstructured":"32. Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. Lancet 2014;383:69-82.","journal-title":"Lancet"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"330","DOI":"10.2337\/db09-1620","article-title":"Predicting adult-onset autoimmune diabetes: clarity from complexity","volume":"59","author":"Leslie","year":"2010","unstructured":"33. Leslie RD. Predicting adult-onset autoimmune diabetes: clarity from complexity. Diabetes 2010;59:330-1.","journal-title":"Diabetes"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"34. Honeyman MC, Stone NL, Harrison LC. T-cell epitopes in type 1 diabetes autoantigen tyrosine phosphatase IA-2: potential for mimicry with rotavirus and other environmental agents. Mol Med 1998;4: 231-9. PMID: 9606176","DOI":"10.1007\/BF03401920"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.4049\/jimmunol.0900709","article-title":"Evidence for molecular mimicry between human T cell epitopes in rotavirus and pancreatic islet autoantigens","volume":"184","author":"Honeyman","year":"2010","unstructured":"35. Honeyman MC, Stone NL, Falk BA, Nepom G, Harrison LC. Evidence for molecular mimicry between human T cell epitopes in rotavirus and pancreatic islet autoantigens. J Immunol 2010;184:2204-10.","journal-title":"J Immunol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.2337\/diabetes.49.8.1319","article-title":"Association between rotavirus infection and pancreatic islet autoimmunity in children at risk of developing type 1 diabetes","volume":"49","author":"Honeyman","year":"2000","unstructured":"36. Honeyman MC, Coulson BS, Stone NL. Association between rotavirus infection and pancreatic islet autoimmunity in children at risk of developing type 1 diabetes. Diabetes 2000;49:1319-24.","journal-title":"Diabetes"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1093\/ije\/24.5.984","article-title":"Increase in incidence of insulin-dependent diabetes mellitus among children in Finland","volume":"24","author":"Tuomilehto","year":"1995","unstructured":"37. Tuomilehto J, Virtala E, Karvonen M, et al. Increase in incidence of insulin-dependent diabetes mellitus among children in Finland. Int J Epidemiol 1995;24: 984-92.","journal-title":"Int J Epidemiol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.2337\/diacare.23.10.1516","article-title":"Diabetes Mondiale (DiaMond) Project Group","volume":"23","author":"Karvonen","year":"2000","unstructured":"38. Karvonen M, Viik-Kajander M, Moltchanova E, Libman I, LaPorte R, Tuomilehto J. Incidence of childhood type 1 diabetes worldwide. Diabetes Mondiale (DiaMond) Project Group. Diabetes Care 2000;23: 1516-26.","journal-title":"Diabetes Care"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1001\/jamapediatrics.2018.4578","article-title":"Association of rotavirus vaccination with the incidence of type 1 diabetes in children","volume":"173","author":"Perrett","year":"2019","unstructured":"39. Perrett KP, Jachno K, Nolan TM, Harrison LC. Association of rotavirus vaccination with the incidence of type 1 diabetes in children. JAMA Pediatr 2019;173: 280-2.","journal-title":"JAMA Pediatr"},{"key":"ref39","unstructured":"40. Department of Health & Human Services, State Government of Victoria, Australia. Vaccine history timeline. Available at: https:\/\/www2.health.vic.gov.au\/public-health\/immunisation\/immunisation-schedule-vaccine-eligibility-criteria\/vaccine-history-timeline (accessed August 2, 2021)."},{"key":"ref40","doi-asserted-by":"publisher","first-page":"7727","DOI":"10.1038\/s41598-019-44193-4","article-title":"Lower incidence rate of type 1 diabetes after receipt of the rotavirus vaccine in the United States, 2001-2017","volume":"9","author":"Rogers","year":"2019","unstructured":"41. Rogers MAM, Basu T, Kim C. Lower incidence rate of type 1 diabetes after receipt of the rotavirus vaccine in the United States, 2001-2017. Sci Rep 2019;9:7727.","journal-title":"Sci Rep"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1093\/infdis\/jiaa168","article-title":"Rotavirus and type 1 diabetes-is there a connection? A synthesis of the evidence","volume":"222","author":"Burke","year":"2020","unstructured":"42. Burke RM, Tate JE, Jiang B, Parashar UD. Rotavirus and type 1 diabetes-is there a connection? A synthesis of the evidence. J Infect Dis 2020;222:1076-83.","journal-title":"J Infect Dis"}],"container-title":["Rambam Maimonides Medical Journal"],"original-title":[],"link":[{"URL":"https:\/\/www.rmmj.org.il\/userimages\/1242\/2\/PublishFiles\/1264Article.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T09:36:24Z","timestamp":1730885784000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.rmmj.org.il\/issues\/51\/articles\/1264"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,25]]},"references-count":42,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,10,25]]}},"URL":"https:\/\/doi.org\/10.5041\/rmmj.10450","relation":{},"ISSN":["2076-9172"],"issn-type":[{"type":"electronic","value":"2076-9172"}],"subject":[],"published":{"date-parts":[[2021,10,25]]}}}